The total return over the past 12 months is +57.85% vs. +19.98% for the S&P 500. So far it's up +25.48% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +57.85% | (6.13%) | (7.92%) | (3.44%) | +6.04% | +8.37% |
| Total Return CAGR | +57.85% | (6.13%) | (7.92%) | (3.44%) | +6.04% | +8.37% |
| Revenue CAGR | (0.49%) | (0.08%) | (3.19%) | (1.21%) | +4.97% | +8.95% |
| Net Income CAGR | (45.44%) | (32.07%) | (15.32%) | (14.10%) | (1.68%) | +17.21% |
| EPS CAGR | (45.90%) | +5.04% | (18.67%) | (5.38%) | +5.47% | +15.69% |
| Free Cash Flow CAGR | +59.89% | +38.05% | (11.63%) | (0.80%) | +5.37% | +8.84% |
| Operating Cash Flow CAGR | +36.01% | +26.31% | +0.48% | (2.98%) | +4.25% | +6.70% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Biogen Inc. (BIIB)
| Year | Start price | End price | BIIB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $175.99 | $220.83 | +25.48% | +13.55% | +11.93% |
| 2025 | $152.92 | $175.99 | +15.09% | +17.72% | (2.63%) |
| 2024 | $258.77 | $152.92 | (40.91%) | +24.89% | (65.80%) |
| 2023 | $276.92 | $258.77 | (6.55%) | +26.19% | (32.74%) |
| 2022 | $239.92 | $276.92 | +15.42% | (18.17%) | +33.59% |
| 2021 | $244.86 | $239.92 | (2.02%) | +28.74% | (30.76%) |
| 2020 | $296.73 | $244.86 | (17.48%) | +18.37% | (35.85%) |
| 2019 | $300.92 | $296.73 | (1.39%) | +31.22% | (32.61%) |
| 2018 | $318.57 | $300.92 | (5.54%) | (4.56%) | (0.98%) |
| 2017 | $283.58 | $318.57 | +12.34% | +21.70% | (9.36%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
